Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Erratum

Erratum To: UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines

Authors: Guoyi Wu, Linan Xu, Nan Lin, Bo Liu, Mark A Feitelson

Published in: BMC Cancer | Issue 1/2014

Login to get access

Excerpt

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. In addition, it has been brought to our attention that an Authors Contributions section was not included in the published article. In this correction we rectify these mistakes. The full list of authors and the Authors Contributions section are reported below and the Acknowledgements section has been modified accordingly. We apologize for any inconvenience this oversight may have caused. …
Literature
1.
Guoyi W, Linan X, Nan L, Bo L: UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines. BMC Cancer. 2013, 13: 167-10.1186/1471-2407-13-167.CrossRef
Metadata
Title
Erratum To: UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines
Authors
Guoyi Wu
Linan Xu
Nan Lin
Bo Liu
Mark A Feitelson
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-216

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Multiple pregnancies, hepatitis C, and risk for hepatocellular carcinoma in Egyptian women

Research article

Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer

Research article

Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer

Research article

MicroRNA profile in very young women with breast cancer

Reviewer acknowledgement

Reviewer acknowledgement 2013

Research article

The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits